LDHA and neoplasm: One key issue with targeting CSC in clinical trials is the lack of validated biomarkers of CSC activity/response, which can be easily measured in the lab using mammospheres, ALDH+ expression and the gold standard limiting dilution model, measuring in vivo tumour initiaiton32.